Issue 48, 2020, Issue in Progress

The construction of the novel magnetic prodrug Fe3O4@DOX and its antagonistic effects on hepatocarcinoma with low toxicity

Abstract

Doxorubicin (DOX) is widely used as a chemotherapeutic agent for liver cancer. However, its clinical applications are greatly restricted by its nonselective cytotoxicity. A novel magnetic prodrug, Fe3O4@DOX, was designed, synthesized and characterized, and Fe3O4 and DOX were connected by the peptide CGGAAN. The magnetic prodrug Fe3O4@DOX was successfully synthesized with average sizes of 95 nm and 322.5 nm by TEM (transmission electron microscopy) and Malvern Zetasizer instrument respectively. The maximum emission wavelength shifted from 594 nm for free DOX to 615 nm for conjugated DOX in the synthesized Fe3O4@DOX. Both free DOX and Fe3O4@DOX show strong cytotoxicity to legumain overexpressing PLC through apoptosis. Similarly, Fe3O4@DOX and DOX equally reduced tumor volume and induced cell apoptosis in tumor tissues, while the former significantly maintained body weight and extended the life of nude mice, therefore serving as a promising nanocarrier for liver cancer treatment.

Graphical abstract: The construction of the novel magnetic prodrug Fe3O4@DOX and its antagonistic effects on hepatocarcinoma with low toxicity

Article information

Article type
Paper
Submitted
23 Feb 2020
Accepted
06 Jul 2020
First published
05 Aug 2020
This article is Open Access
Creative Commons BY-NC license

RSC Adv., 2020,10, 28965-28974

The construction of the novel magnetic prodrug Fe3O4@DOX and its antagonistic effects on hepatocarcinoma with low toxicity

J. Li, L. Li, Y. Lv, H. Zou, Y. Wei, F. Nie, W. Duan, M. Sedike, L. Xiao and M. Wang, RSC Adv., 2020, 10, 28965 DOI: 10.1039/D0RA01729A

This article is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported Licence. You can use material from this article in other publications, without requesting further permission from the RSC, provided that the correct acknowledgement is given and it is not used for commercial purposes.

To request permission to reproduce material from this article in a commercial publication, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party commercial publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements